Overfølsomhedsreaktioner inklusive anafylakse er ikke blevet opserveret i kliniske forsøg, og immunogeniciteten af ziconotid indgivet via IT synes at være lav.
Hypersensitivity reactions including anaphylaxis have not been observed during clinical trials and the immunogenicity of ziconotide administered by the IT route appears to be low.